In a groundbreaking development, the recent trials of a drug developed by Ireland-based psychedelics biotech company GH Research have showcased its potential in treating treatment-resistant depression. The mid-stage clinical trial, comprising 81 participants, revealed a significant reduction in
The search for effective treatments for Parkinson's disease has been long and arduous, with researchers globally dedicating countless hours to uncover potential therapies. One promising candidate, exenatide, a GLP-1 drug traditionally used to treat Type 2 diabetes, recently underwent scrutiny in
The 2024 Biopharma Technology Landscape report by Benchling, a leading R&D cloud software company, reveals the transformative impact of artificial intelligence (AI) and automation on biopharma research and development (R&D). The report highlights how large biopharma companies are leveraging these
The biopharma industry is grappling with a persistent wave of layoffs as companies navigate financial constraints and strategic realignments. Despite hopes for a reprieve in 2024, the sector saw a 3% increase in layoffs compared to the previous year. This trend underscores the ongoing challenges
The latest study from the Perelman School of Medicine at the University of Pennsylvania and Penn Medicine's Abramson Cancer Center provides compelling evidence that CAR T cell therapy does not induce secondary cancers. This finding comes from an extensive analysis of data involving over 700
Polymetastatic cancer, a condition where cancer has spread to more than 10 spots throughout the body, often leaves patients with limited treatment options. Recent advancements in cancer therapy have focused on high-precision radiation treatments to combat this extensive metastasis. Researchers from
